Skip to main content

Table 1 HIV testing, CD4 cell count assessment, and ARV regimens initiated during pregnancy in Rwanda, from July 2006 through to December 2008 (N= 32 sites)

From: Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens

  2006 (Jul-Dec)
N (%)
2007
N (%)
2008
N (%)
Total
N (%)
p**
(2007 vs. 2008)
Total number of sites 14 19 32 - -
   Full package 5 (35.7%) 15 (79%) 18 (56%) - -
Counseling and testing of pregnant women in ANC:      
   First ANC visit 4,520 15,469 20,685 40,674 -
   Known to be HIV positive NA 135 (0.9%) 291 (1.4%) 426 (1%) -
   Tested for HIV 4,452 (98%) 15,231 (98%) 20,564 (99%) 40,247 (99%) <0.0001
   Tested HIV positive 234 (5%) 741 (5%) 647 (3%) 1,622 (4%) <0.0001
Partner counseling and HIV testing NA 8,652 (57%) 15,463 (75%) 24,115 (67%)$ <0.0001
CD4 cell count assessment during pregnancy      
   Total HIV positive in ANC 234 876 938 2,048 -
   Screened for CD4 cell counts 140 (60%) 610 (70%) 658 (70%) 1,408 (69%) 0.81
   Received CD4 cell count results¶¶ NA 564 (92%) 647 (98%) 1,211 (96%)$ <0.0001
   CD4 cell counts < 350 cells/mm3 NA 132 (23%) 160 (25%) 292 (24%)$ 0.59
Enrolment of HIV positive women into care and treatment NA 180/443 (41%)@ 564/938 (60%) 744/1381 (54%)$ -
HAART initiation for women with CD4 cell counts < 350 cells/mm3 NA 114/132 (86%) 127/160 (79%) 241/292 (83%)$ 0.12
Total HIV positive in ANC 234 876 938 2,048  
All ARV regimens initiated during pregnancy 155 (66%) 667 (76%) 638 (68%) 1460 (71%)  
   Dual (AZT/NVP) prophylaxis 55 (35.5%) 386 (58%) 403 (63%) 844 (58%)  
   HAART for life NA 114 (17%) 127 (20%) 241 (16%)  
   sd-nvp only 100 (64.5%) 34 (5%) 21 (3%) 155 (11%)  
   Short-course HAART NA 133 (20%) 87 (14%) 220 (15%)  
More efficacious ARV regimens (dual ARV, or HAART for life or sc-HAART) 55 (35.5%) 633 (95%) 617 (97%) 1325 (89%)  
  1. $ Percentage calculated based on 2007 and 2008 data only.
  2. NA indicates data not available or not routinely reported in the program monthly report.
  3. Indicates the number of HIV+ pregnant women giving blood for CD4 testing and includes women of known HIV+ status.
  4. ¶¶ Indicates the number of HIV+ women receiving CD4 results in a given period and might include women screened in a previous time period. This number is used as a denominator to compute the proportion of women with CD4 cell counts < 350 cells/mm3, which reflects the number of women whose results were available and who returned for enrolment in health regimens and subsequent HAART initiation.
  5. @ Data available only for the period from July - December 2007. The denominator was limited to the total number of HIV positive women during the same period.
  6. ** Chi-square test, two-sided p-value comparing the 2007 to 2008 data only.